Methodology: each issue's direction is a live signal — long/short opens or holds a position, neutral means flat, and every direction change opens, flips, or closes it. Returns are direction-aware (a short gains when the price falls) and compound across positions from first observation to the latest issue. "Price move" is the stock's own raw change, shown separately. Neither represents actual portfolio performance.
Brief History (4 issues)
Down another 1.49% with RSI(7) deeply oversold at 20.3, but the merger-talks variable remains unresolved. The 38.2% consensus upside is tempting while Berenberg has already warned of persistent pressure; sidelines.
RSI(7) at 22.5 is tempting and 37% implied upside is substantial, but this is not a technical mispricing — the mere existence of merger talks is an open variable that cannot be priced. Berenberg put it plainly: shares stay depressed while it's unresolved. Taking a direction before there are answers on deal structure, consideration, and the antitrust path means paying for someone else's uncertainty. Wait for a statement.
Down 1.3% to $169.47 after a 10.9% weekly slide — no basing structure yet in this pharma pullback; sidelines
A defensive mega-pharma below all its averages usually grinds sideways rather than bouncing; gap repair needs a fresh catalyst. Dividend and valuation set the floor, but there's no near-term entry signal.